(Total Views: 567)
Posted On: 02/11/2021 9:17:30 PM
Post# of 145247
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
This excerpt seems pretty exciting to me:
additionally, in the present disclosure, leronlimab was found to be unexpectedly effective in preventing tumor growth in mouse models lacking T cells, indicating that leronlimab also modulates immunological responses and promote anti-tumor effects through NK cells, B cells, or both. Accordingly, the ability of leronlimab to modulate activity triggered by binding the CCR5 axis on non-T cells, for example, on NK cells, B cells, or both, was determined. Also, importantly, it was found that leronlimab is surprisingly effective in preventing tumor growth in mouse models based solely on its activity relative to non-T cells; thus, suggesting a non-T cell therapeutic approach.
additionally, in the present disclosure, leronlimab was found to be unexpectedly effective in preventing tumor growth in mouse models lacking T cells, indicating that leronlimab also modulates immunological responses and promote anti-tumor effects through NK cells, B cells, or both. Accordingly, the ability of leronlimab to modulate activity triggered by binding the CCR5 axis on non-T cells, for example, on NK cells, B cells, or both, was determined. Also, importantly, it was found that leronlimab is surprisingly effective in preventing tumor growth in mouse models based solely on its activity relative to non-T cells; thus, suggesting a non-T cell therapeutic approach.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)